292 related articles for article (PubMed ID: 30896886)
1. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer.
Shi R; Wang C; Fu N; Liu L; Zhu D; Wei Z; Zhang H; Xing J; Wang Y
Oncol Rep; 2019 May; 41(5):3015-3026. PubMed ID: 30896886
[TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.
Chen WJ; Wang H; Tang Y; Liu CL; Li HL; Li WT
Chin J Cancer; 2010 Feb; 29(2):151-7. PubMed ID: 20109342
[TBL] [Abstract][Full Text] [Related]
4. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
[TBL] [Abstract][Full Text] [Related]
5. Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells.
Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
J Pharm Pharmacol; 2021 Jun; 73(7):922-927. PubMed ID: 33885909
[TBL] [Abstract][Full Text] [Related]
6. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
7. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
[TBL] [Abstract][Full Text] [Related]
9. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer.
Shi R; Liu L; Wang F; He Y; Niu Y; Wang C; Zhang X; Zhang X; Zhang H; Chen M; Wang Y
Cell Signal; 2020 Dec; 76():109810. PubMed ID: 33069797
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
12. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
[TBL] [Abstract][Full Text] [Related]
13. The PI3K subunits, P110α and P110β are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer.
Zhang L; Li Y; Wang Q; Chen Z; Li X; Wu Z; Hu C; Liao D; Zhang W; Chen ZS
Mol Cancer; 2020 Jan; 19(1):10. PubMed ID: 31952518
[TBL] [Abstract][Full Text] [Related]
14. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.
Ross DD; Yang W; Abruzzo LV; Dalton WS; Schneider E; Lage H; Dietel M; Greenberger L; Cole SP; Doyle LA
J Natl Cancer Inst; 1999 Mar; 91(5):429-33. PubMed ID: 10070941
[TBL] [Abstract][Full Text] [Related]
15. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer.
Zhang B; Wang J; Liu W; Yin Y; Qian D; Zhang H; Shi B; Li C; Zhu J; Zhang L; Gao L; Wang C
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2479-2487. PubMed ID: 27601168
[TBL] [Abstract][Full Text] [Related]
17. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells.
Jang JY; Kim MK; Jeon YK; Joung YK; Park KD; Kim CW
Exp Mol Med; 2012 Apr; 44(4):251-9. PubMed ID: 22198296
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
[TBL] [Abstract][Full Text] [Related]
19. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
[TBL] [Abstract][Full Text] [Related]
20. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]